Sort   by:  
 Page size 
TranscriptomicsThe transcriptional response of Cryptococcus neoformans to ingestion by Acanthamoeba castellanii and murine macrophages
Virulence of Cryptococcus neoformans for mammals was proposed to emerge from evolutionary pressures on its natural environment by protozoan predators, which selected for strategies that allow survival within macrophages. In fact, Acanthamoeba castellanii ingests yeast cells, which then replicate int...
ORGANISM(S): Cryptococcus neoformans 
2013-03-14 | E-GEOD-45027 | biostudies-arrayexpress
ProteomicsBeta-Adrenergic stimulation of breast cancer MDA-MB-231 and bone tropic MDA-MB-231-BoM 1833 cell line secretome
In this study, we aimed to study the effect of Beta-2 Adrenergic Receptor stimulation on secreted proteins in triple negative breast cancer cell lines. We also wanted to compare protein expression in parental or bone tropic metastatic cell lines and how they respond to adrenergic signaling.
ORGANISM(S): Homo sapiens (Human) 
2023-07-20 | PXD030371 | Pride
Human Lc-msms Breast cancer Conditioned medium Secreted 
UnknownSocioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women.
Not available
S-EPMC9071365 | biostudies-literature
UnknownClinical outcomes of patients with unsuccessful mechanical thrombectomy versus best medical management of medium vessel occlusion stroke in the middle cerebral artery territory.
Not available
S-EPMC12284089 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownFive insights from the Global Burden of Disease Study 2019.
Not available
S-EPMC7116361 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
Sort   by:  
 Page size